The Stage | Markus Baumann, Chief Corporate Strategy Officer, CMR Surgical

Why It Matters

CMR’s aggressive expansion could accelerate the NHS’s robotic surgery adoption, cutting costs and improving patient outcomes, while offering investors a foothold in a rapidly expanding medical‑technology market.

Key Takeaways

• CMR Surgical ranks second globally in soft‑tissue robotics.
• Versius robot offers portable, modular, ergonomic alternative to legacy systems.
• Under 7% of surgeries use robots; market poised for growth.
• NHS plans to spend £10 billion on robotic procedures within decade.
• £1 billion financing fuels CMR’s expansion against established competitors.

Summary

Markus Baumann, Chief Corporate Strategy Officer at CMR Surgical, outlines the company’s rapid ascent in the surgical‑robotics sector. CMR, a British scale‑up, now sits second worldwide in soft‑tissue robotic systems, driven by its Versius platform—a portable, modular, ergonomically designed alternative to traditional, bulky robots.

Baumann highlights that less than 7% of global surgeries currently employ robotics, underscoring a massive untapped market. In the UK, the NHS projects that nine in ten procedures will involve robotic assistance within a decade, committing over £10 billion to the transition. CMR has secured more than £1 billion in financing to scale production and challenge entrenched incumbents.

He likens CMR to a “British David” confronting industry Goliaths, emphasizing Versius’s unique value proposition and the expected improvements in surgical efficiency, patient recovery times, and hospital stay durations. The company’s growth narrative is reinforced by concrete figures: a £1 billion capital raise and a clear path to capture a larger share of a market dominated by a few players.

The implications are twofold: healthcare systems stand to reduce waiting lists and lower costs while delivering better outcomes, and investors gain exposure to a high‑growth, disruptive technology poised to reshape a multi‑billion‑dollar industry.

Original Description

In this episode of The Stage, Markus Baumann, Chief Corporate Strategy Officer at CMR Surgical, shares his perspective on the rapid evolution of surgical robotics.

With global adoption still in its early stages, Markus explains the scale of the opportunity to improve surgical efficiency and patient outcomes, and how CMR is positioning itself as a leading challenger in a transformative market.

About The Stage

The Stage is a video series by London Stock Exchange Group celebrating the people behind the markets. Each episode features industry leaders sharing insights, milestones and the stories that shaped their journey.

👉 Ready to take centre stage? Register your interest:

https://lseg.group/4pLOFUx

#TheStage #CMRSurgical

LSEG (London Stock Exchange Group) is a diversified international markets infrastructure business —earning our clients’ trust for over 300 years. That legacy of customer-focused excellence ensures that you can rely on our expertise in capital formation, intellectual property and risk and balance sheet management. As global leaders in financial indexing, benchmarking and analytic services, we offer unrivalled access to international capital markets. Our high-performance technology solutions enable companies worldwide to access funds for growth and development. And with our Data & Analytics, Capital Markets and Post Trade divisions, we provide a comprehensive, integrated suite of trusted financial market infrastructure services that help our customers pursue—and achieve—their ambitions. That’s how we make a difference— ensuring people can meet their potential—worldwide.

Follow us on LinkedIn (linkedin.com/company/london-stock-exchange-group) and Twitter (@LSEGplc).